DayOne Catalyst Project: Oonida
One of the pillars of BaselArea.swiss’ DayOne (www.DayOne.swiss) strategy is to drive Catalyst projects – collaborative approaches to bottleneck issues in Healthcare innovation. These are “wicked problems” that can only be solved collaboratively. Therefore, Catalyst Projects focus on challenges to which it is difficult to find solutions within the current industry structures.
DayOne Catalyst project workshop (img: Frank Kumli)
The access to healthcare data is one of the best-known bottleneck issues in healthcare innovation and is being addressed by Oonida. The Basel based not-for-profit company is building a citizen centric platform where health data can be shared between patients and all relevant healthcare stakeholders. As a neutral steward OoNiDa aims to improve the efficiency within the ecosystem and overall population health by encouraging free flow of information in the health ecosystem so services and care can be delivered more efficiently and innovation can be stimulated.
New insights and connections
On behalf of OoNiDa DayOne brought together 15 volunteering healthcare innovators across industry and disciplines from the Basel ecosystem. During a full-day workshop at the DayOne Innovation Lab in the Technologiepark Basel, the OoNiDa management was able to validate and refine their business model and to come up with a minimal viable product that could be launched and tested in the local market.
“It is a unique experience for a startup in the very early stage like ours, to get access to some of the brightest minds in the Basel Healthcare Innovation Ecosystem. Not only did we gain new insights but could also make most valuable connections to future partners and customers of our platform”, stated Andy Bushell, Founder and CEO of OoNiDa.
… about the workshop with Oonida and about our Catalyst projects www.dayone.ch/projects.
If you or your organization would like to launch a Catalyst project, please contact email@example.com
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More